Session » Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 275

A Comparison of the Clinical Features and Natural History of Autoimmune Interstitial Lung Disease Vs. Idiopathic Pulmonary Fibrosis

9:00AM-11:00AM: Abstract Number: 251

A New Genetic Mutation in TNF Receptor Associated Periodic Syndrome (TRAPS)

9:00AM-11:00AM: Abstract Number: 246

Adult Autoinflammatory Disease Frequency and Our Diagnostic Experience in an Adult Autoinflammatory Clinic

9:00AM-11:00AM: Abstract Number: 261

Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-Center Experience

9:00AM-11:00AM: Abstract Number: 272

Are the Autoimmune/Inflammatory Syndrome Induced By Adjuvants (ASIA) and the Undifferentiated Connective Tissue Disease (UCTD) Related to Each Other? a Case-Control Study of Environmental Exposures

9:00AM-11:00AM: Abstract Number: 267

Association of CXCL10 and CXCL13 Levels with Disease Activity and Cutaneous Manifestation in Active Adult-Onset Still’s Disease

9:00AM-11:00AM: Abstract Number: 270

Biologic Agents in Refractory Adult Still’s Disease: Better Response Rates and Acceptable Safety with Anakinra and Tocilizumab

9:00AM-11:00AM: Abstract Number: 262

Canakinumab Therapy in Patients with Familial Mediterranean Fever

9:00AM-11:00AM: Abstract Number: 264

Clinical Phenotype and Response to Treatment in Adult-Onset Still’s Disease with MEFV Variants

9:00AM-11:00AM: Abstract Number: 266

Effect of Tocilizumab on Adults Onset Still’s Disease in Korean Population: Multicenter Retrospecitve Study of 24 Cases

9:00AM-11:00AM: Abstract Number: 248

Efficacy and Safety of Canakinumab in Patients with CAPS Aged <24 Months: Results from an Open-Label, Multicenter, Phase III Trial

9:00AM-11:00AM: Abstract Number: 279

Ehlers-Danlos Syndrome Hypermobility Type (Type III) Is Associated with Rheumatological Conditions

9:00AM-11:00AM: Abstract Number: 259

How Safe IT Is to TREAT Pregnant FMF Patients with Anakinra ?

9:00AM-11:00AM: Abstract Number: 271

Investigating an Auto-Inflammatory Component of COPD That Contributes to Progressive Decline in Lung Function Despite Smoking Cessation

9:00AM-11:00AM: Abstract Number: 257

Investigation of the Arterial Stiffness and Associated Factors in Patients with Familial Mediterranean Fever

9:00AM-11:00AM: Abstract Number: 269

Items of Yamaguchi Criteria Might be Associated with Disease Severity and Prognosis in Adult-Onset Still’s Disease

9:00AM-11:00AM: Abstract Number: 276

Long-Term Outcome in Mixed Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 278

Mitral Valve Prolapse in Patients with Joint Hypermobility Syndrome

9:00AM-11:00AM: Abstract Number: 253

Multiple Serum Cytokine Profiling to Identify Specific Molecular Networks in Attacks of Familial Mediterranean Fever

9:00AM-11:00AM: Abstract Number: 250

Postvaccination Antibody Titer Data in CAPS Patients Aged 28 Days to 4 Years Treated with Canakinumab: Results of an Open-Label Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 273

Progression Predictive Factors in Patients with Undifferentiated Connective Tissue Disease: A Cohort Study

9:00AM-11:00AM: Abstract Number: 252

Pyrin (MEFV) Mutations in New York: Revisiting the Mount Sinai Experience with Periodic Fever and Serositis

9:00AM-11:00AM: Abstract Number: 258

Quality of Life Changes with Canakinumab Therapy in Adults with Colchicine Resistant FMF

9:00AM-11:00AM: Abstract Number: 277

Rituximab in Refractory Mixed Connective Tissue Disease: An Observational Study

9:00AM-11:00AM: Abstract Number: 247

Severe Inflammation Following Vaccination Against Streptococcus Pneumoniae in Patients with Cryopyrin-Associated Periodic Syndromes

9:00AM-11:00AM: Abstract Number: 274

Shrinking Lung Syndrome in Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 254

The Interleukin-1 Inhibitor Canakinumab for Familial Mediterranean Fever: Long-Term Beneficial Effect in a Cohort of 13 Patients

9:00AM-11:00AM: Abstract Number: 256

The Predominant Attack Type and Associated Clinical-Laboratory Conditions in Patients with Familial Mediterranean Fever

9:00AM-11:00AM: Abstract Number: 268

TLR4 Endogenous Ligand S100A8/A9 Levels in Adult-Onset Still’s Disease and Their Association with Disease Activity and Clinical Manifestations

9:00AM-11:00AM: Abstract Number: 265

Tocilizumab Compared with Anakinra in Refractory Adult-Onset Still’s Disease. Multicenter Study of 75 Patients

9:00AM-11:00AM: Abstract Number: 260

Tocilizumab Is Effective in the Treatment of AA Amyloidosis Secondary to Familial Mediterranean Fever

9:00AM-11:00AM: Abstract Number: 263

Use of Serum Ferritin and Heme Oxygenase 1 for the Diagnosis of Adult-Onset Still’s Disease: A Preliminary Report of Multicenter Study

9:00AM-11:00AM: Abstract Number: 255

What Acute Phase Reactants Accurately Identify Patients Who Will Develop Amyloidosis in Familial Mediterranean Fever? a Systematic Review

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].